Clinical Trial

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

Study acronym: CELESTE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-09-04; most recent amendment 2026-06-19.
Status change: Not Yet Recruiting → Recruiting 2025-12-01
Trial Details
NCT Number NCT07161544
Lead Sponsor AAVantgarde Bio Srl
Collaborators: AAVantgarde Bio UK Ltd
Conditions Stargardt Disease
Enrollment 75 participants
Start Date 2025-09-29
Primary Completion 2032-07 (estimated)
Study Completion 2032-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-30